381 related articles for article (PubMed ID: 12233894)
1. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
Thomson AB; Marshall JK; Hunt RH; Provenza JM; Lanza FL; Royer MG; Li Z; Blank MA;
J Rheumatol; 2002 Sep; 29(9):1965-74. PubMed ID: 12233894
[TBL] [Abstract][Full Text] [Related]
2. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae.
Lanza F; Schwartz H; Sahba B; Malaty HM; Musliner T; Reyes R; Quan H; Graham DY
Am J Gastroenterol; 2000 Nov; 95(11):3112-7. PubMed ID: 11095326
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.
Lanza FL; Hunt RH; Thomson AB; Provenza JM; Blank MA
Gastroenterology; 2000 Sep; 119(3):631-8. PubMed ID: 10982755
[TBL] [Abstract][Full Text] [Related]
4. Influence of Helicobacter pylori eradication therapy on the occurrence of gastrointestinal events in patients treated with conventional nonsteroidal antiinflammatory drugs combined with omeprazole.
Bannwarth B; Dorval E; Caekaert A; Barthelemy P
J Rheumatol; 2002 Sep; 29(9):1975-80. PubMed ID: 12233895
[TBL] [Abstract][Full Text] [Related]
5. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.
Lanza F; Sahba B; Schwartz H; Winograd S; Torosis J; Quan H; Reyes R; Musliner T; Daifotis A; Leung A
Am J Gastroenterol; 2002 Jan; 97(1):58-64. PubMed ID: 11808969
[TBL] [Abstract][Full Text] [Related]
6. Effects of alendronate on gastric and duodenal mucosa.
Lanza F; Rack MF; Simon TJ; Lombardi A; Reyes R; Suryawanshi S
Am J Gastroenterol; 1998 May; 93(5):753-7. PubMed ID: 9625122
[TBL] [Abstract][Full Text] [Related]
7. Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects.
Stoltz RR; Harris SI; Kuss ME; LeComte D; Talwalker S; Dhadda S; Hubbard RC
Am J Gastroenterol; 2002 Jan; 97(1):65-71. PubMed ID: 11808971
[TBL] [Abstract][Full Text] [Related]
8. The clinical tolerability profile of alendronate.
Watts N; Freedholm D; Daifotis A
Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
[TBL] [Abstract][Full Text] [Related]
10. Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: a prospective placebo-controlled, double-blind randomized trial.
Feldman M; Cryer B; Mallat D; Go MF
Am J Gastroenterol; 2001 Jun; 96(6):1751-7. PubMed ID: 11419825
[TBL] [Abstract][Full Text] [Related]
11. Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa.
Thomson AB; Appleman S; Keelan M; Wallace JL
Dig Dis Sci; 2003 Feb; 48(2):308-14. PubMed ID: 12643608
[TBL] [Abstract][Full Text] [Related]
12. Duodenal Helicobacter pylori associated duodenal ulcer depend on gastric Helicobacter pylori status.
Vilaichone RK; Mahachai V; Tumwasorn S; Nunthapisud P; Wisedopas N; Kullavanijaya P
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S97-102. PubMed ID: 12188459
[TBL] [Abstract][Full Text] [Related]
13. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
15. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
[TBL] [Abstract][Full Text] [Related]
16. Upper gastrointestinal toxicity of alendronate.
Lowe CE; Depew WT; Vanner SJ; Paterson WG; Meddings JB
Am J Gastroenterol; 2000 Mar; 95(3):634-40. PubMed ID: 10710050
[TBL] [Abstract][Full Text] [Related]
17. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
18. Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study.
Schaeverbeke T; Broutet N; Zerbib F; Combe B; Bertin P; Lamouliatte H; Perié F; Joubert-Collin M; Mégraud F
Am J Gastroenterol; 2005 Dec; 100(12):2637-43. PubMed ID: 16393213
[TBL] [Abstract][Full Text] [Related]
19. Helicobacter pylori and gastric adaptation to repeated aspirin administration in humans.
Konturek JW; Dembiński A; Konturek SJ; Domschke W
J Physiol Pharmacol; 1997 Sep; 48(3):383-91. PubMed ID: 9376621
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.
Ilter E; Karalok H; Tufekci EC; Batur O
Climacteric; 2006 Apr; 9(2):129-34. PubMed ID: 16698659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
